Erasca announced on October 15, 2026, that it is terminating the employment of Chief Operating Officer Nicholas (Nik) Chetwyn effective November 2, 2026. The decision follows a strategic realignment of leadership responsibilities to support the development and potential commercialization of its RAS-targeting programs. COO duties are transitioning to other members of the company's leadership team to streamline the reporting structure. Erasca operates in the biotechnology industry, focusing on developing therapies targeting RAS-driven cancers.
